Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges [Yahoo! Finance]
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting [Yahoo! Finance]
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting